Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a scale used by doctors to measure this — confirm with trial site)
• People diagnosed with endometrial cancer of any tissue type (a pathology report may be required)
• People whose cancer has a specific genetic profile: either mismatch repair deficiency (MMR-D), high microsatellite instability (MSI-H), or a POLE gene mutation — testing results may be required, and POLE-mutated cases are limited to a small number per group (confirm with trial site)
• People whose cancer has been found to have certain gene changes related to how DNA is silenced (hypermethylation of MMR gene promoters), which also makes them potentially eligible
• People who have completed full surgical staging and have been found to have Stage III or Stage IVA disease, with no remaining measurable cancer detectable after surgery
• People whose surgery was completed between 3 and 12 weeks before the first day of treatment, and who have sufficiently recovered from surgery
• People who are not able to become pregnant, or people who have had a negative blood pregnancy test within 7 days before starting treatment and agree to use effective contraception from the start of the trial until 150 days after the last dose
• People who agree not to breastfeed during the trial or for 150 days after the last dose
• People whose blood test results show that their kidneys, liver, bone marrow, and thyroid are functioning at a level that meets the trial's requirements (tests must be done within 14 days of starting treatment — confirm with trial site)

Who may not be able to join:

• People who have previously received chemotherapy, targeted therapy, or experimental treatment specifically for endometrial cancer (people previously treated for a different cancer who are now in remission may be considered at the treating doctor's discretion)
• People who have previously received certain types of immunotherapy drugs (anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents) for endometrial cancer
• People who are not suitable for radiation therapy, including those who have had pelvic radiation before, have had radiation to a large portion of their bone marrow recently, or have a known history of certain abnormal connections between organs (fistulas) involving the bladder, bowel, or vagina
• People with a known serious allergic reaction to the study drug (Dostarlimab) or any of its ingredients
• People with a diagnosed immune system disorder, or who are currently taking steroid medications or other immune-suppressing treatments (with some exceptions for low-dose or inhaled steroids — confirm with trial site)
• People with active tuberculosis
• People with current active, non-infectious lung inflammation (pneumonitis)
• People with a history of scarring or inflammation of the lung tissue (interstitial lung disease)
• People with an active infection currently being treated with intravenous antibiotics
• People with certain serious medical conditions that could interfere with the trial, including a recent heart attack (within 90 days), uncontrolled seizures, unstable spinal cord compression, severe lung disease, or superior vena cava syndrome (confirm with trial site)
• People who have previously had a bone marrow transplant from a donor, or a solid organ transplant
• People with an active or recent history (within the past 3 years) of certain autoimmune or inflammatory conditions, such as lupus, rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, or similar conditions, or people who require immune-suppressing treatment for such conditions (some conditions such as vitiligo, stable hypothyroidism, or psoriasis not requiring systemic treatment may be exceptions — confirm with trial site)
• People living with HIV who do not have an undetectable viral load on effective treatment within the past 6 months
• People with active hepatitis B or C who do not meet specific viral load requirements (confirm with trial site)
• People who have received a live vaccine within 30 days before starting the trial (some flu vaccines are allowed — confirm with trial site)
• People who are unwilling or unable to give written informed consent, or who are unable to follow the trial requirements for its full duration

Important: Always verify eligibility with the trial site directly before applying.